Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia

NCT ID: NCT01614990

Last Updated: 2024-03-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2021-12-31

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of repeated oral administration of macimorelin at different doses daily for 1 week for the treatment of cancer cachexia.

Conditions

Cancer Cachexia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Macimorelin

Group Type: ACTIVE_COMPARATOR

Macimorelin

Intervention Type: DRUG

Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

placebo (Powerade®) daily for 7 days.

Interventions

Macimorelin

Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.

Intervention Type: DRUG

Placebo

placebo (Powerade®) daily for 7 days.

Intervention Type: DRUG

Other Intervention Names

AEZS-130; Powerade®

Eligibility Criteria

Inclusion Criteria

1. Subjects ≥18 years of age with histological diagnosis of incurable cancer (solid tumor),

2. ECOG performance status of 0-2,

3. Presence of cancer-related cachexia defined as an involuntary weight loss of at least 5% of the pre-illness body weight over the previous 6 months, and

4. Provide written informed consent prior to screening.

Exclusion Criteria

1. Obesity (body weight >140 Kg);

2. Recent active excessive alcohol or illicit drug use;

3. Severe depression as determined by the investigator;

4. Other causes of cachexia such as: Liver disease (AST or ALT > 3x normal levels); renal failure (creatinine >1.5 mg/dL), untreated thyroid disease, class III-IV CHF, AIDS, severe COPD requiring use of home O2;

5. Inability to increase food intake (e.g., esophageal obstruction, intractable nausea and vomiting);

6. Any condition that would prevent the subject from performing the research procedures (e.g. unstable coronary artery disease);

7. Use of growth hormone, megestrol, Marinol, or any other anabolic agents, appetite stimulants (including corticosteroids other than dexamethasone at the time of IV chemotherapy administrations), tube feeding, or parenteral nutrition during the 1 month prior to entering the study;

8. Recent administration (less than 1 week) of highly emetogenic chemotherapy (Hesketh scale class 4-5); subjects may otherwise be undergoing chemotherapy.

9. Being female and pregnant, breast-feeding or of childbearing potential. (Note: Lack of childbearing potential for female patients is satisfied by: a) being post menopausal; b) being surgically sterile; c) practicing contraception with an oral contraceptive, intra-uterine device, diaphragm, or condom with spermicide for the duration of the study; or d) being sexually inactive. Confirmation that the patient is not pregnant will be established by a negative serum hCG pregnancy test at the time of enrollment.

10. Co-administration of drugs that prolong QT interval, CYP3A4 inducers, QTc equal to or greater than 450ms at screening, or other investigational agents (a wash-out period of five times the half life of drugs that prolong QT will be allowed with approval of prescriber).

11. Conditions that would preclude from successfully scanning subjects in MRI:

• Claustrophobia (this would make lying in the scanner very uncomfortable); b. having a pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, steel worker, or other implants; c. History of Seizures d. History of head injuries resulting in loss of consciousness > 10 minutes.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

VA Office of Research and Development

FED

Sponsor Role: collaborator

Baylor College of Medicine

OTHER

Sponsor Role: collaborator

AEterna Zentaris

INDUSTRY

Sponsor Role: collaborator

Garcia, Jose M., MD, PhD

INDIV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jose M Garcia, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Washington and Veterans Affairs Puget Sound Health Care System

Locations

Veterans Affairs Puget Sound Health Care System

Seattle, Washington, United States

Countries

United States

References

Herodes M, Anderson LJ, Shober S, Schur EA, Graf SA, Ammer N, Salas R, Marcelli M, Garcia JM. Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia. J Cachexia Sarcopenia Muscle. 2023 Apr;14(2):835-846. doi: 10.1002/jcsm.13191. Epub 2023 Mar 1.

Reference Type: RESULT

PMID: 36860137 (View on PubMed)

Maldonado M, Molfese DL, Viswanath H, Curtis K, Jones A, Hayes TG, Marcelli M, Mediwala S, Baldwin P, Garcia JM, Salas R. The habenula as a novel link between the homeostatic and hedonic pathways in cancer-associated weight loss: a pilot study. J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):497-504. doi: 10.1002/jcsm.12286. Epub 2018 Mar 25.

Reference Type: DERIVED

PMID: 29575771 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

00954

Identifier Type: -

Identifier Source: org_study_id